Wikisage, the free encyclopedia of the second generation, is digital heritage
Levetiracetam: Difference between revisions
Jump to navigation
Jump to search
m (rfz) |
m (full paper) |
||
| Line 1: | Line 1: | ||
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat [[epilepsy]]. It is the S-enantiomer of [[etiracetam]], structurally similar to the prototypical nootropic drug [[piracetam]]. | (S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat [[epilepsy]]. It is the S-enantiomer of [[etiracetam]], structurally similar to the prototypical nootropic drug [[piracetam]]. | ||
Levetiracetam inhibits high-voltage- | Levetiracetam inhibits high-voltage-activated calcium channels and reduces calcium release from intraneural stores<ref>[http://www.indianpediatrics.net/nov2013/1033.pdf newer antiepileptic drugs]</ref> | ||
==[[levetiracetam XR|Extended release]]== | ==[[levetiracetam XR|Extended release]]== | ||
| Line 30: | Line 30: | ||
Caviness J. N. | Caviness J. N. | ||
[http://www.ncbi.nlm.nih.gov/pubmed/24037428 Treatment of myoclonus] | [http://www.ncbi.nlm.nih.gov/pubmed/24037428 Treatment of myoclonus] | ||
deWolfe & Szafarski | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750522/pdf/fneur-04-00121.pdf Levetiracetam use in the critical care setting] | |||
{{Wikidata|Q417227}} | {{Wikidata|Q417227}} | ||
Revision as of 00:45, 30 March 2016
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat epilepsy. It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Levetiracetam inhibits high-voltage-activated calcium channels and reduces calcium release from intraneural stores[1]
Extended release
Links
In myoclonic astatic epilepsy should be used with caution in children[2]
ATC
Trinka E., et al 2015 Pharmacotherapy for Status Epilepticus Drugs 75:1499
Safraski J.-P.2015
Jackson J.-L. et al.2015
Caviness J. N. Treatment of myoclonus
deWolfe & Szafarski Levetiracetam use in the critical care setting
- ↑ newer antiepileptic drugs
- ↑ Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paediatrics 15 6
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AX14&showdescription=yes